Canine atopic dermatitis is among the most common causes of pruritus of dogs. Management is multimodal with an emphasis on minimizing flares, maximizing relief of clinical signs, and providing a good quality of life for dogs and owners.
In this open-label clinical trial, 160 dogs with nonseasonal atopic dermatitis and pruritus were treated for 8 weeks with ultramicronized palmitoylethanolamide (PEA). PEA, a naturally occurring bioactive lipid, has documented anti-inflammatory properties and is produced in response to stress and tissue damage. Owners assessed pruritus via a 10-cm visual analog scale and quality of life with a validated questionnaire. Veterinarians assessed inflammation and lesions using the Canine Atopic Dermatitis Lesion Index (CADLI). Dogs were evaluated on days 0, 28, and 56, with a midstudy telephone evaluation on day 15.
Sign in to continue reading this article
Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.